GlassScriptPhysician profile
Douglas B Woodruff
NPI 1972779023
$4,360.36
in general payments reported to CMS, 2019-2025
25 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $647 · 2021: $765 · 2022: $529 · 2023: $872 · 2024: $49.35 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $537.95 | 2019-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $522.93 | 2019-2023 | Invega Trinza, Spravato |
| Abbvie INC. | $443.09 | 2021-2025 | Vraylar |
| Sunovion Pharmaceuticals INC. | $434.01 | 2019-2022 | |
| Allergan, INC. | $352.67 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $311.56 | 2023-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $305.78 | 2019-2023 | Trintellix |
| Adlon Therapeutics L.P. | $209.04 | 2020-2021 | |
| Bausch Health US, LLC | $149.02 | 2021-2022 | |
| Lundbeck LLC | $140.72 | 2019-2023 | Rexulti |
| Corium, LLC | $129.69 | 2022-2023 | Azstarys |
| Indivior INC. | $116.53 | 2023-2025 | Sublocade |
| Eisai INC. | $112.59 | 2020-2021 | |
| Almatica Pharma LLC | $87.29 | 2022-2023 | Loreev Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.72 | 2021-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $74.33 | 2023 | Dyanavel Xr |
| Sage Therapeutics, LLC | $70.54 | 2020 | |
| Merck Sharp & Dohme LLC | $64.73 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $56.28 | 2022-2023 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $41.79 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $30.05 | 2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $26.94 | 2020 | |
| Braeburn INC. | $26.26 | 2025 | Brixadi |
| Ironshore Pharmaceuticals INC. | $20.14 | 2023 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $12.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Woodruff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.